Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with other antiretroviral agents is not recommended in Delstrigo product labels. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir would be possible from a pharmacokinetic standpoint. Coadministration with ritonavir increased doravirine AUC by 3.5 fold and Cmin by 2.9 fold. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure. In a combined analysis of several clinical studies with tenofovir-DF (300 mg) and atazanavir/ritonavir (300/100 mg), tenofovir AUC, Cmax and Cmin increased by 37%, 34% and 29%, respectively. Thus, patients should be closely monitored for tenofovir-associated adverse events, including renal disorders. Atazanavir/r should be dosed at 400/100 mg once daily in presence of tenofovir-DF and an H2-receptor antagonist due to the resulting decrease in atazanavir exposure.